| abstract |
The present invention relates to an oral preparation of N-hydroxy-4- {5- [4- (5-isopropyl-2 -methyl- 1, 3-thiazol-4-yl)p henoxy] pentoxyl -benzamidine having improved bioavailability . More particularly, the present invention relates to an oral preparation comprising: N-hydroxy-4- {5- [4- (5-isopropyl-2-methyl-l, 3-thiazol-4- yl) phenoxy] pentoxy} -benzamidine or pharmaceutically acceptable salt thereof; and one or more carbonates selected from the group consisting of alkalimetal carbonate, alkalimetal bicarbonate and alkaline earth metal carbonate, and/or one or more disintegrants selected from the group consisting of sodium starch glycolate, carmellose calcium and croscarmellose sodium. The oral preparation according to the present invention inhibits gelation of N-hydroxy-4- {5- [4- (5-isopropyl-2-methyl-l, 3-thiazol-4-yl) p henoxy] pentoxy} -benzamidine or pharmaceutically acceptable salt thereof in the early stage of release, which increases dissolution rate and remarkably raises bioavailability. |